Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Safety of Almonertinib”

21 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 21 results

Testing effectiveness (Phase 2)UnknownNCT04922138
What this trial is testing

Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns

Who this might be right for
Lung Cancer
Baohui Han 104
Large-scale testing (Phase 3)Active Not RecruitingNCT04687241
What this trial is testing

Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations

Who this might be right for
Non-small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 192
Large-scale testing (Phase 3)UnknownNCT04951648
What this trial is testing

A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 220
Testing effectiveness (Phase 2)UnknownNCT04785742
What this trial is testing

Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR

Who this might be right for
Safety of Almonertinib
Sun Yat-sen University 40
Testing effectiveness (Phase 2)Looking for participantsNCT06951464
What this trial is testing

BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Sichuan University 40
Large-scale testing (Phase 3)Enrolling By InvitationNCT04762459
What this trial is testing

Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection

Who this might be right for
Non-small Cell Lung Carcinoma
Chinese Academy of Medical Sciences 606
Early research (Phase 1)UnknownNCT05430386
What this trial is testing

Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 174
Testing effectiveness (Phase 2)UnknownNCT05810350
What this trial is testing

Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles

Who this might be right for
Non-small Cell Lung Cancer
Three Gorges Hospital of Chongqing University 40
Large-scale testing (Phase 3)Looking for participantsNCT06417008
What this trial is testing

HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hansoh BioMedical R&D Company 1,080
Testing effectiveness (Phase 2)UnknownNCT04882345
What this trial is testing

Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment

Who this might be right for
Lung CancerEGFR Gene Mutation
Shanghai Chest Hospital 40
Testing effectiveness (Phase 2)UnknownNCT04978753
What this trial is testing

The Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung CancerBrain Metastases
Li-kun Chen 54
Large-scale testing (Phase 3)Looking for participantsNCT04841811
What this trial is testing

MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model.

Who this might be right for
Lung Cancer
Guangdong Association of Clinical Trials 192
Testing effectiveness (Phase 2)UnknownNCT04785729
What this trial is testing

Almonertinib Combined With Pyrotinib in the Treatment of Advanced NSCLC Patients With HER-2 Amplification/Mutation After EGFR-TKI Resistance

Who this might be right for
Safety
Sun Yat-sen University 36
Large-scale testing (Phase 3)UnknownNCT04870190
What this trial is testing

Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

Who this might be right for
NSCLC
Shanghai Chest Hospital 232
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05778149
What this trial is testing

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

Who this might be right for
AumolertinibAnlotinibTP53+2 more
Tianjin Medical University Cancer Institute and Hospital 47
Not applicableLooking for participantsNCT06481566
What this trial is testing

Efficacy and Safety of Almonertinib Combined With Stereotactic Body Radiotherapy (SBRT) in the Treatment of Non-small Cell Lung Cancer With EGFR Sensitive Mutation: a Single-arm, Open-label Clinical Trial

Who this might be right for
Non-small Cell Lung Cancer
Chongqing University Cancer Hospital 30
Large-scale testing (Phase 3)Active Not RecruitingNCT04923906
What this trial is testing

Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations

Who this might be right for
Non-small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 624
Testing effectiveness (Phase 2)UnknownNCT05662813
What this trial is testing

Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy

Who this might be right for
Non-small Cell Lung Cancer
West China Hospital 55
Early research (Phase 1)Looking for participantsNCT07130916
What this trial is testing

Aumolertinib in European Participants With Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 20
Large-scale testing (Phase 3)UnknownNCT06110663
What this trial is testing

HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

Who this might be right for
Non-Small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 314
Load More Results